2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1540

Cardiovascular Risk Management in Rheumatoid Arthritis Patients
Abstract Number: 1505

Carotid Artery Atherosclerosis in Patients with Active Rheumatoid Arthritis: Predictors of Plaque Occurrence and Progression over 24 Weeks
Abstract Number: 300

Causes of Creatine Kinase Levels Greater Than 1,000 IU/L in Patients Referred to Rheumatology
Abstract Number: 1876

Caveolin 1 Gene Variants May Effect Disease Progression in Systemic Sclerosis Related Interstitial Lung Disease
Abstract Number: 2009

CC-Chemokine Receptor 7 (CCR7) Deficiency Reduces Early Structural and Functional Features of Disease in a Murine Model of Osteoarthritis
Abstract Number: 2602

CCP Antibody Negativity Is Associated with Higher Fatigue in Rheumatoid Arthritis
Abstract Number: 1070

CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE
Abstract Number: 10

CD13/Aminopeptidase N Contributes to Angiogenesis and Monocyte Chemotaxis in Rheumatoid Arthritis
Abstract Number: 794

CD163+ Macrophages Display Mixed Polarizations in Discoid Lupus Skin
Abstract Number: 1102

CD19+CD24-CD38hi B-Cell Subset: A Potential Biomarker for IgG4-Related Disease
Abstract Number: 3028

CD1d Regulates iNKT Cell Autoreactivity
Abstract Number: 982

CD4+CD146+ T Cells: The Primed IL-17 Secreting Cells in the Pathogenesis of Psoriatic Arthritis
Abstract Number: 1370

CD40/CD40L Pathway Is Associated with Increased Oxidative Burst and Neutrophil Extracellular Traps Release in Behcet´s Disease
Abstract Number: 3087

Cell Bound Complement Activation Products in Multianalyte Assay with Algorithm Have Utility in Distinguishing Primary Fibromyalgia from Systemic Lupus Erythematosus
Abstract Number: 719

Cell of Origin of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].